Previous Close | 2.3100 |
Open | 2.3200 |
Bid | 2.4600 x 3100 |
Ask | 2.5000 x 3200 |
Day's Range | 2.2650 - 2.5000 |
52 Week Range | 1.9300 - 6.5000 |
Volume | |
Avg. Volume | 1,533,293 |
Market Cap | 368.845M |
Beta (5Y Monthly) | 2.66 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.7050 |
Earnings Date | Aug 03, 2022 - Aug 08, 2022 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 6.70 |
Subscribe to Yahoo Finance Plus to view Fair Value for ABUS
WARMINSTER, Pa., May 26, 2022 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today announced that its abstract on a preclinical oncology study for one of Arbutus’ oral PD-L1 inhibitor compounds designed to reawaken the immune system, has been selected for publication at the American Society of Clinical Oncology (ASCO) Annual
The Pennsylvania Biotechnology Center of Bucks County and its affiliated organizations have generated an economic impact of $7.3 billion for the state during the past six years, according to a new study. The analysis, conducted by KLIOS Consulting economist Richard M. Stein, found that between the beginning of 2016 and the end of 2021, the biotech center produced a $2.3 billion direct impact tied to spending and economic activity at the center, and another $3.5 billion in indirect spending elsewhere in Pennsylvania tied to initial economic activity at the center. The remaining $1.5 billion represents the center's "induced impact," which is economic benefit related to additional household spending created from biotech center activities and related indirect economic activity.
WARMINSTER, Pa., May 17, 2022 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today announced that William Collier, Arbutus’ President and Chief Executive Officer, will present at the H.C. Wainwright Global Investment Conference on Tuesday, May 24, 2022, at 11:30 am ET in Miami, FL. A live webcast of the presentation can be ac